The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress
Abstract
Hyperglycaemia is a major contributor to diabetic cardiovascular disease with hyperglycaemia-induced endothelial dysfunction recognized as the initiating cause. Coagulation pathway-regulated proteinase-activated receptors (PARs) that can regulate vascular tone in vivo cause eNOS-mediated endothelium-dependent vasodilation; but, the impact of hyperglycaemia on this vasodilatory action of PAR stimulation and the signalling pathways involved are unknown. We hypothesized that vascular sodium-glucose co-transporter 2 activity and hyperglycaemia-induced oxidative stress involving Src-kinase, EGF receptor-kinase, Rho-kinase and protein-kinase-C biochemical signalling pathways would compromise PAR2-mediated endothelium-dependent vasodilation. Using an organ culture approach, wherein murine aorta rings were maintained for 24 h at hyperglycaemic 25 mM versus euglycaemic 10 mM glucose, we observed severely blunted acetylcholine/muscarinic and PAR2-mediated endothelial eNOS/NO-dependent vasodilation. PEG-catalase, superoxide-dismutase, and NADPH-oxidase inhibition (VAS2870) and either SGLT2-inhibition (canagliflozin/dapagliflozin/empagliflozin) or antioxidant gene induction (sulforaphane), prevented the hyperglycaemia-induced impairment of PAR2-mediated vasodilation. Similarly, inhibition of Src-kinase, EGF receptor-kinase, protein kinase-C and Rho-kinase also preserved PAR2-mediated vasodilation in tissues cultured under hyperglycaemic conditions. Thus, intracellular hyperglycaemia, that can be prevented with an inhibitor of the SGLT2 cotransporter that was identified in the vascular tissue and tissue-derived cultured endothelial cells by qPCR, western blot and immunohistochemistry, leads to oxidative stress that compromises PAR2-mediated NOS-dependent vasodilation by an NAPDH oxidase/reactive-oxygen-species-triggered signalling pathway involving EGFR/Src/Rho-kinase and PKC. The data point to novel antioxidant therapeutic strategies including use of an SGLT2 inhibitor and sulforaphane to mitigate hyperglycaemia-induced endothelial dysfunction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin and other drugs used for T2DM, like the SGLT2 inhibitors, may also reduce hyperglycemia-induced elevated endothelial ROS, independent of negative effects on complex 1, such as via inhibition of NADPH oxidase or blocking the entry of glucose into the endothelium (32, 107–109, 187, 188)”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [188]
Citations
Cites
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112797 · Cited by 16,303
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Role of nrf2 in oxidative stress and toxicity
Ma, Q. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140320 · Cited by 4,903
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Thrombin signalling and protease-activated receptors
Coughlin, S. R. (2000) · Nature · doi:10.1038/35025229 · Cited by 2,495
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947
Landmesser, U., Dikalov, S., Price, S. R., McCann, L., Fukai, T., Holland, S. M., Mitch, W. E., & Harrison, D. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200314172 · Cited by 1,660
Flagged first, then by citations
Research works printed but not linked: 1
- Triggle, 2008, The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Timely topics in medicine, Cardiovasc. Dis., 12
Cited by
Sorted by citations
Items 101–115 of 115
Aziz, M. W., Mohamed, K. O., Khalifa, A. K., Farag, D. B., & Mahmoud, Z. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00998c · Cited by 1
Timar, B., Braha, A., Grigorică, L., Gaiţă, L., & Timar, R. Z. (2020) · Timişoara Medical Journal · doi:10.35995/tmj20200101 · Cited by 1
Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome?
Sanoudou, D., Mantzoros, C. S., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155309 · Cited by 1
Inserra, F., Forte, E. H., Elbert, A. E., Waisman, G. D., & Castellaro, C. (2023) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v57i3.728 · Cited by 1
Aging and Redox Pathways in Diabetes
Suarez, C. S. B., Merino-Chavez, H., Rajagopalan, K., Triggle, C. R., & Kinaan, M. (2021) · Healthy ageing and longevity · doi:10.1007/978-3-030-84965-8_16 · Cited by 1
Az akut canagliflozinkezelés kivédi a miokardiális iszkémia-reperfúziós károsodást patkánymodellen
Sayour, A. A., Ruppert, M., Oláh, A., Benke, K., Benkő, R., Horváth, E. M., Korkmaz‐Icöz, S., Loganathan, S., Karck, M., Merkely, B. P., et al. (2020) · Cardiologia Hungarica · doi:10.26430/chungarica.2020.50.6.417
Sewage sludge treatment by membrane anaerobic system (MAS)
Musliha, M. (2010) · UMP Institutional Repository (Universiti Malaysia Pahang)
AÇÃO DOS ISGLT2 NO HIPERTENSO DIABÉTICO, QUANDO INDICAR?
Bianco, H. T. (2021) · Revista Brasileira de Hipertensão · doi:10.47870/1519-7522/20212804283-7
Canagliflozin Reduces the Contractile Response of Isolated Heart of Normal Adult Rats
Elkattawy, H. A., Mahmoud, A. N., Al-Zahaby, S. A., Elsherbiny, N. M., Ebrahim, H. A., Elsherbini, D. M. A., & Hadhod, S. (2022) · International Journal of Morphology · doi:10.4067/s0717-95022022000501300
Progress of SGLT2 inhibitors in the treatment of common immune-related nephropathies
Hu, G., Wu, Y., Chen, F., & Tang, J. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04141-2
Ma, M., Lian, S., Kraft, P., Mayer, T., Sayour, A. A., Karck, M., Szabo, G. B., & Korkmaz‐Icöz, S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117601
Protective effect of SGLT2 inhibitors on cardiovascular remodeling
Matsushita, K. (2022) · theses.fr (ABES) · doi:10.70675/a461e811zf66fz4443za0efz481618885013
EGFR as a context-dependent modulator of endothelial inflammation: A systematic review
Giacinti, G. M., Altoé, L. S. C., da Silva, A. M. Á., Coelho, F. F., Baldam, R. D. L., Louro, I. D., & Meira, D. D. (2026) · Cytokine · doi:10.1016/j.cyto.2026.157183
Wang, Y., Chen, Z., Wu, Y., Yu, X., Li, J., Liu, L., 胡昌炽, & 赵永烈 (2026) · Synapse · doi:10.1002/syn.70062
Metadata
- Authors
- El-Daly, M., Pulakazhi Venu, V. K., Saifeddine, M., Mihara, K., Kang, S., Fedak, P. W. M., Alston, L. A., Hirota, S. A., Ding, H., Triggle, C. R., & Hollenberg, M. D.
- Affiliations
- University of Calgary (CA)
- Weill Cornell Medical College in Qatar (QA)
- Corresponding author
- Hollenberg, Morley D.
- ORCID
- Venue
- Vascular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 109
- Pages
- 56-71
- ISSN
- 1537-1891 (ISSN-L)
- OpenAlex
- W2808400246
- Cited by
- 117
- References
- 78
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 11 · 2023: 14 · 2022: 16 · 2021: 26 · 2020: 15 · 2019: 14 · 2018: 3
- FWCI
- 9.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Vascular Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Qatar Foundation National Priorities Research Program (NPRP: 08165-3-054), 4-910-3-244)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Keywords
- hyperglycemia, protease-activated receptor 2, endothelium-dependent vasodilation, endothelial dysfunction, SGLT2, SGLT2 inhibitors, oxidative stress, NADPH oxidase, reactive oxygen species, Src kinase, EGF receptor, Rho kinase, protein kinase C, sulforaphane, antioxidant therapy, diabetic cardiovascular disease, aortic endothelium
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Antioxidants, Aorta, Dose-Response Relationship, Drug, Endothelium, Vascular, Hyperglycemia, Hypoglycemic Agents, Male, Mice, Inbred C57BL, Mitochondria, Nitric Oxide, Organ Culture Techniques, Protein Kinase C, Vasodilation, Signal Transduction, Oxidative Stress, src-Family Kinases, Endothelial Cells, Receptor, PAR-2, Sodium-Glucose Transporter 2, Nitric Oxide Synthase Type II, rho-Associated Kinases, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
